[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.170.75.58. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 313
Citations 0
Invited Commentary
February 5, 2020

Pasireotide and Corticosteroids for Prevention of Pancreatic Fistula—Over-HYPed?

Author Affiliations
  • 1Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia
JAMA Surg. Published online February 5, 2020. doi:10.1001/jamasurg.2019.6020

As pancreatic surgeons, we know all too well how hard it is to carry out randomized clinical trials in our field. Therefore, in striving for the best evidence-based solutions to combat the sequelae of pancreatectomies, we are grateful to Tarvainen and colleagues1 for providing us the Hydrocortisone vs Pasireotide in Reducing Pancreatic Surgery Complications trial in this issue of JAMA Surgery. We are offered a demonstration that perioperative administration of hydrocortisone is not significantly worse compared with the more-expensive option of pasireotide in terms of overall complication burden (measured by the Comprehensive Complication Index) following different types of pancreatectomies. Pasireotide is, however, associated with a lower rate of clinically relevant postoperative pancreatic fistulas in the subgroup of distal pancreatectomies. Unfortunately, the article is unclear on which of these outcomes (overall burden vs fistula) is the real focus of the investigation.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×